DSCSA data exchange has matured into daily operations, but the coming NDC-12 shift and a national licensure standard add new work streams before old ones are fully settled.
Publication|Articles|December 10, 2024
- Pharmaceutical Commerce - December 2024
- Volume 19
- Issue 6
Pharmaceutical Commerce - December 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Commerce December 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 2 years ago
Traceability's Latest Curvealmost 2 years ago
An Appreciation for RFIDalmost 2 years ago
Conference Connect: Tackling the Issues that Matter in the Access Spacealmost 2 years ago
Did Industry Fumble the DSCSA Deadline?almost 2 years ago
Caught Beneath the Surface: The Hidden Potential of Patient Dataalmost 2 years ago
Navigating the Landscape of Global AI Governancealmost 2 years ago
Why AI Advances in CGT Require Getting Data Rightalmost 2 years ago
Policy and Population Healthalmost 2 years ago
The Advantages of New Medicare Rx Payment PlanAdvertisement
Related to this article
Liberty Dewey of Cardinal Health breaks down the NDC-12 transition timeline, the four work streams driving it and why the biggest risk sits in trading partner handoffs.
Go behind the scenes of LogiPharma USA 2026 with program director Charleen Ring and McKesson's Chris Van Norman in this Pharma Pulse special.
An FTC settlement moved one PBM aggregator onshore, but manufacturers still lack contract-level clarity on what affiliated fees actually buy.
Simvera PSP applies queueing science so manufacturers can test the cost and patient impact of hub staffing decisions before locking them in.
Gregg Gorniak explains how AI, RFID and serialized data are helping trading partners move DSCSA compliance from a regulatory checkbox to a source of shared operational value.
As HRSA's 340B Rebate Model Pilot moves toward its effective date, Valerie Bandy, PharmD, of Tecsys explains what drug-by-drug rebate tracking really demands from hospital and health system pharmacies.
Pharma pricing shifts beyond PBM rebates as Medicare and cash channels reshape launches, WAC cuts and access strategies.
Advertisement
Advertisement